Pathogenesis-based therapies in ichthyoses

Dermatologic Therapy

Volumn 26, Issue 1, 2013, Pages 46-54

  Lai Cheong, Joey E ^a   Elias, Peter M ^b   Paller, Amy S ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

ceramides; cholesterol; fatty acids; ichthyosis; lanosterol; pathogenesis

Indexed keywords

CHOLESTEROL; MEVINOLIN;

CHILD SYNDROME; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHONDRODYSPLASIA; DESMOSTEROLOSIS; DISORDERS OF LIPID METABOLISM; GAUCHER DISEASE; GENETIC DISORDER; HUMAN; ICHTHYOSIS; LATHOSTEROLOSIS; LIPIDOSIS; MOLECULAR PATHOLOGY; NETHERTON DISEASE; REFSUM DISEASE; REVIEW; SC4MOL DEFICIENCY; SJOEGREN LARSSON SYNDROME; SLOS SYNDROME; SYSTEMIC DISEASE; X CHROMOSOME LINKED DISORDER; X LINKED DOMINANT CHONDRODYSPLASIA; X LINKED ICHTHYOSIS;

ABNORMALITIES, MULTIPLE; ADMINISTRATION, TOPICAL; CHOLESTEROL; DRUG COMBINATIONS; GENETIC DISEASES, X-LINKED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; ICHTHYOSIS; LIMB DEFORMITIES, CONGENITAL; LOVASTATIN; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 84873438529     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01528.x     Document Type: Review

References (77)

1. Oji V, Traupe H,. Ichthyosis: clinical manifestations and practical treatment options. Am J Clin Dermatol 2009: 10: 351-364.
2. Elias PM, Williams ML, Crumrine D, Schmuth M,. Ichthyoses: clinical, biochemical, pathogenic and diagnostic assessment. Basel, Switzerland: Karger Publishers, 2010. 144 pp.
3. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M,. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008: 49: 697-714.
4. Elias PM, Crumrine D, Paller A, Rodriguez-Martin M, Williams ML,. Pathogenesis of the cutaneous phenotype in inherited disorders of cholesterol metabolism: therapeutic implications for topical treatment of these disorders. Dermatoendocrinol 2011: 3: 100-106.
5. Paller AS, van Steensel MA, Rodriguez-Martin M, et al. Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism. J Invest Dermatol 2011: 131: 2242-2248.
6. Vahlquist A, Ganemo A, Virtanen M,. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008: 88: 4-14.
7. Werchau S, Toberer F, Enk A, Helmbold P,. Keratitis-ichthyosis-deafness syndrome: response to alitretinoin and review of literature. Arch Dermatol 2011: 147: 993-995.
8. Uitto J, Christiano AM, McLean WH, McGrath JA,. Novel molecular therapies for heritable skin disorders. J Invest Dermatol 2012: 132: 820-828.
9. Rizzo WB, S'Aulis D, Jennings MA, Crumrine DA, Williams ML, Elias PM,. Ichthyosis in Sjogren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion. Arch Dermatol Res 2010: 302: 443-451.
10. Chan YM, Merkens LS, Connor WE, et al. Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res 2009: 65: 681-685.
11. Szabo GP, Olah AV, Kozak L, et al. A patient with Smith-Lemli-Opitz syndrome: novel mutation of the DHCR7 gene and effects of therapy with simvastatin and cholesterol supplement. Eur J Pediatr 2010: 169: 121-123.
12. Porter FD, Herman GE,. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 2011: 52: 6-34.
13. Porter FD,. Human malformation syndromes due to inborn errors of cholesterol synthesis. Curr Opin Pediatr 2003: 15: 607-613.
14. Moebius FF, Fitzky BU, Glossmann H,. Genetic defects in postsqualene cholesterol biosynthesis. Trends Endocrinol Metab 2000: 11: 106-114.
15. Krakowiak PA, Wassif CA, Kratz L, et al. Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Hum Mol Genet 2003: 12: 1631-1641.
16. Herman GE,. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet 2003: 12 (Spec No 1): R75-R88.
17. Haas D, Kelley RI, Hoffmann GF,. Inherited disorders of cholesterol biosynthesis. Neuropediatrics 2001: 32: 113-122.
18. FitzPatrick DR, Keeling JW, Evans MJ, et al. Clinical phenotype of desmosterolosis. Am J Med Genet 1998: 75: 145-152.
19. He M, Kratz LE, Michel JJ, et al. Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest 2011: 121: 976-984.
20. Singh P, Saxena R, Paila YD, Jafurulla M, Chattopadhyay A,. Differential effects of cholesterol and desmosterol on the ligand binding function of the hippocampal serotonin(1A) receptor: implications in desmosterolosis. Biochim Biophys Acta 2009: 1788: 2169-2173.
21. Rodriguez-Acebes S, de la Cueva P, Fernandez-Hernando C, et al. Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-delta24-reductase-deficient cell line. Biochem J 2009: 420: 305-315.
22. Sabatini K, Mattila JP, Kinnunen PK,. Interfacial behavior of cholesterol, ergosterol, and lanosterol in mixtures with DPPC and DMPC. Biophys J 2008: 95: 2340-2355.
23. Bjorkhem I,. Are side-chain oxidized oxysterols regulators also in vivo? J Lipid Res 2009: 50 (Suppl.): S213-S218.
24. Cooper MK, Wassif CA, Krakowiak PA, et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003: 33: 508-513.
25. Happle R,. X-chromosome inactivation: role in skin disease expression. Acta Paediatr Suppl 2006: 95: 16-23.
26. DeBose-Boyd RA,. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 2008: 18: 609-621.
27. Braverman N, Lin P, Moebius FF, et al. Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hunermann syndrome. Nat Genet 1999: 22: 291-294.
28. Derry JM, Gormally E, Means GD, et al. Mutations in a delta 8-delta 7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. jderry@immunex.com. Nat Genet 1999: 22: 286-290.
29. Grange DK, Kratz LE, Braverman NE, Kelley RI,. CHILD syndrome caused by deficiency of 3beta-hydroxysteroid-delta8, delta7-isomerase. Am J Med Genet 2000: 90: 328-335.
30. Ikegawa S, Ohashi H, Ogata T, et al. Novel and recurrent EBP mutations in X-linked dominant chondrodysplasia punctata. Am J Med Genet 2000: 94: 300-305.
31. Kelley RI, Herman GE,. Inborn errors of sterol biosynthesis. Annu Rev Genomics Hum Genet 2001: 2: 299-341.
32. Happle R,. Lyonization and the lines of Blaschko. Hum Genet 1985: 70: 200-206.
33. Happle R,. X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet 1979: 53: 65-73.
34. Anstey AV, Ryan A, Rhodes LE, et al. Characterization of photosensitivity in the Smith-Lemli-Opitz syndrome: a new congenital photosensitivity syndrome. Br J Dermatol 1999: 141: 406-414.
35. Yu H, Patel SB,. Recent insights into the Smith-Lemli-Opitz syndrome. Clin Genet 2005: 68: 383-391.
36. Bommannan D, Menon GK, Okuyama H, Elias PM, Guy RH,. Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 1992: 9: 1043-1047.
37. Feingold KR,. The regulation and role of epidermal lipid synthesis. Adv Lipid Res 1991: 24: 57-82.
38. Clayton PT, Kalter DC, Atherton DJ, Besley GT, Broadhead DM,. Peroxisomal enzyme deficiency in X-linked dominant Conradi-Hunermann syndrome. J Inherit Metab Dis 1989: 12 (Suppl. 2): 358-360.
39. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM,. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 1996: 85: 643-648.
40. Brunetti-Pierri N, Corso G, Rossi M, et al. Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet 2002: 71: 952-958.
41. Jiang XS, Backlund PS, Wassif CA, Yergey AL, Porter FD,. Quantitative proteomics analysis of inborn errors of cholesterol synthesis: identification of altered metabolic pathways in DHCR7 and SC5D deficiency. Mol Cell Proteomics 2010: 9: 1461-1475.
42. Rossi M, D'Armiento M, Parisi I, et al. Clinical phenotype of lathosterolosis. Am J Med Genet A 2007: 143A: 2371-2381.
43. Andersson HC, Kratz L, Kelley R,. Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet 2002: 113: 315-319.
44. Bergner EA, Shapiro LJ,. Metabolism of 3H-dehydroepiandrosterone sulphate by subjects with steroid sulphatase deficiency. J Inherit Metab Dis 1988: 11: 403-415.
45. Elias PM, Williams ML, Maloney ME, et al. Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest 1984: 74: 1414-1421.
46. Epstein EH Jr, Krauss RM, Shackleton CH,. X-linked ichthyosis: increased blood cholesterol sulfate and electrophoretic mobility of low-density lipoprotein. Science 1981: 214: 659-660.
47. Long SA, Wertz PW, Strauss JS, Downing DT,. Human stratum corneum polar lipids and desquamation. Arch Dermatol Res 1985: 277: 284-287.
48. Ranasinghe AW, Wertz PW, Downing DT, Mackenzie IC,. Lipid composition of cohesive and desquamated corneocytes from mouse ear skin. J Invest Dermatol 1986: 86: 187-190.
49. Williams ML, Elias PM,. Stratum corneum lipids in disorders of cornification: increased cholesterol sulfate content of stratum corneum in recessive x-linked ichthyosis. J Clin Invest 1981: 68: 1404-1410.
50. Elias PM, Crumrine D, Rassner U, et al. Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol 2004: 122: 314-319.
51. Zettersten E, Man MQ, Sato J, et al. Recessive x-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol 1998: 111: 784-790.
52. Evers BM, Farooqi MS, Shelton JM, et al. Hair growth defects in Insig-deficient mice caused by cholesterol precursor accumulation and reversed by simvastatin. J Invest Dermatol 2010: 130: 1237-1248.
53. De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996: 12: 52-57.
54. Uchida Y, Cho Y, Moradian S, et al. Neutral lipid storage leads to acylceramide deficiency, likely contributing to the pathogenesis of Dorfman-Chanarin syndrome. J Invest Dermatol 2010: 130: 2497-2499.
55. Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001: 69: 1002-1012.
56. Jansen GA, Ferdinandusse S, Hogenhout EM, Verhoeven NM, Jakobs C, Wanders RJ,. Phytanoyl-CoA hydroxylase deficiency. Enzymological and molecular basis of classical Refsum disease. Adv Exp Med Biol 1999: 466: 371-376.
57. Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997: 17: 190-193.
58. Singh I, Pahan K, Singh AK, Barbosa E,. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes. J Lipid Res 1993: 34: 1755-1764.
59. Menon E, Orso E, Schmitz G, Crumrine D, Elias P,. Abnormalities in ultrastructure of epidermal lamellar bodies and corneocyte lipid envelope in Refsum disease. J Invest Dermatol 2011: 139: S52.
60. Khnykin D, Crumrine D, Uchida Y, et al. Ichthyosis prematurity syndrome: lipid metabolic abnormalities lead to an epidermal barrier defect and predispose to atopy. J Invest Dermatol 2011: 139: S59.
61. Akiyama M,. Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. Arch Dermatol 2006: 142: 914-918.
62. Fischer J,. Autosomal recessive congenital ichthyosis. J Invest Dermatol 2009: 129: 1319-1321.
63. Jiang YJ, Lu B, Kim P, et al. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol 2008: 128: 104-109.
64. Man MM, Feingold KR, Thornfeldt CR, Elias PM,. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996: 106: 1096-1101.
65. Zheng Y, Beier D, Brash A, Elias P, Crumrine D,. Formation and function of the corneocyte lipid envelope. J Invest Dermatol 2011: 286: 24,46-2456.
66. Tsuji S, Choudary PV, Martin BM, et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med 1987: 316: 570-575.
67. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000: 25: 141-142.
68. Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 2011: 131: 1947-1950.
69. Fortugno P, Bresciani A, Paolini C, et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol 2011: 131: 2223-2232.
70. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009: 206: 1135-1147.
71. Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A,. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol 2010: 130: 2736-2742.
72. Li M, Hener P, Zhang Z, Ganti KP, Metzger D, Chambon P,. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J Invest Dermatol 2009: 129: 498-502.
73. Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005: 202: 541-549.
74. Zhang Z, Hener P, Frossard N, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci U S A 2009: 106: 1536-1541.
75. Furio L, Hovnanian A,. When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition. J Invest Dermatol 2011: 131: 2169-2173.
76. Zheng Y, Yin H, Boeglin WE, et al. Lipoxygenases mediate the effect of essential fatty acid in skin barrier formation: a proposed role in releasing omega-hydroxyceramide for construction of the corneocyte lipid envelope. J Biol Chem 2011: 286: 24046-24056.
77. Sandilands A, O'Regan GM, Liao H, et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 2006: 126: 1770-1775.